Press Releases | Longboard Pharmaceuticals

Skip to main navigation

Corporate Menu

About
Our Approach
Patients
Investors
Longboard Life
- Overview
- Culture and Benefits
Contact

Press Releases

Year

November 12, 2024

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

November 7, 2024

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

October 14, 2024

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

October 4, 2024

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 26, 2024

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

September 19, 2024

Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

September 8, 2024

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

September 6, 2024

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

August 28, 2024

Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September

August 26, 2024

Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 31

©2024 Longboard Pharmaceuticals Privacy Policy | Terms of Use

Corporate Menu

About
Our Approach
Patients
Investors
Longboard Life
- Overview
- Culture and Benefits
Contact